Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 6

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 6
---
 or
approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

<div align='center'>4</div>

Additional Information about the Transaction and Where to Find It

In connection with the proposed transaction, NLS
has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant
documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any
other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders
of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS
THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN
THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security
holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important
information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained
by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s
website at www.nlspharma.com.

Participants in the Solicitation

NLS, Kadimastem, and certain of their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders
in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their
direct or indirect interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal
year ended December 31, 2023, which was filed with the SEC on May